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Introduction
Subcapsular Liver Hematoma in Metastatic GIST 
Complicating Imatinib (Gleevec) Therapy 
Sridhar Shankar, M.D.
We report two patients with metastatic gastrointestinal stromal tumor (GIST) who had large subcap-
sular hepatic hematomas that developed while on imatinib mesylate (Gleevec) therapy. We describe 
the pertinent radiologic features of the subcapsular hematomas in these patients, and discuss possible 
etiologies for the bleeding in each patient.
Imatinib mesylate (Gleevec, Novartis Pharmaceuticals 
Corp, East Hanover, NJ) has been used successfully to 
treat chronic myelogenous leukemia [1]. The drug, a ty-
rosine kinase inhibitor, has also shown significant promise 
in clinical trials for gastrointestinal stromal tumor (GIST) 
by arresting and sometimes reversing the progression of 
disease [2, 3]. We report two patients who had an un-
usual, and hitherto unreported response to the drug--large 
subcapsular hepatic hematomas. We describe the pertinent 
radiologic features of the subcapsular hematomas in these 
patients, and discuss possible etiologies for the bleeding in 
each patient.
Case Report 1
A 49-year-old man was diagnosed with GIST when he 
presented with symptoms of bloating, increased abdominal 
size, and decreased appetite. He underwent exploratory 
laparotomy and resection of a circumscribed, nodular, 17 
cm intra-abdominal mass arising from the small intestine. 
Pathology confirmed the diagnosis of GIST, positive for 
the oncogene c-kit. At that time, no other sites of involve-
ment were seen either on CT or during the exploratory 
laparotomy. Approximately one year later he was found 
to have multiple liver metastases on follow-up CT, the 
largest being 6 cm by 5 cm. The extent and number of 
these lesions rendered the patient unsuitable for surgery or 
percutaneous ablation.
The patient was treated with several chemotherapy 
regimens unsuccessfully: carboplatin and taxotere, taxotere 
alone, as well as several experimental chemotherapeutic 
phase 1 drugs. All of these chemotherapeutic drugs were 
found to have limited or no effect, as evidenced by the in-
creasing size of the liver lesions on serial CT scans over 34 
months. The patient was then placed on an experimental 
protocol using STI-571 (imatinib mesylate, marketed as 
Gleevec, Novartis, USA), nearly three years after his prima-
ry tumor was discovered. Before initiation of the drug, he 
had a hemoglobin level of 12.8 gm/dL and a normal WBC 
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Figure 1A. 49-year-old man with metastatic GIST. Contrast 
enhanced axial CT scan through the liver 8 weeks after treat-
ment with imatinib, shows two adjacent liver lesions that 
show cystic areas within them.
Figure 1B. Contrast enhanced axial CT scan through the liver 
at a higher level shows a tumor with internal fluid-fluid level 
(arrow) suggesting intratumoral hemorrhage.
count. He had no fever and liver function tests were within 
normal limits. The patient was started on the drug accord-
ing to protocol requirements, at 600 mg by mouth daily. 
A pre-therapy CT guided percutaneous liver biopsy of the 
largest right lobe lesion revealed metastatic GIST.
A CT scan 8 weeks after initiation of therapy with 
imatinib showed that the liver metastases were reduced in 
size, and demonstrated cystic areas (Fig. 1A). One lesion, 
located immediately lateral to the inferior vena cava (IVC) 
had decreased the most-from a previous measurement 
of 5.2 cm x 4.3 cm, to 3.7 cm x 3.4 cm. This mass also 
demonstrated an intratumoral fluid-fluid level, suggesting 
hemorrhage (Fig. 1B).
Four months after initiation of therapy, the patient 
complained of acute right upper quadrant pain. Hemoglo-
bin was 7.6 gm/dL, compared to the baseline of 12.8 gm/
dL. The patient initially refused a blood transfusion. How-
ever, one week after the acute episode, his hemoglobin was 
8.5 gm/dL and he was now lethargic, easily fatigued, pale, 
and short of breath. A CT scan performed at that time 
revealed a large hepatic subcapsular fluid collection around 
the right lobe, with layering of high-density material, 
consistent with a hematoma (Fig. 1C). The lesion lateral to 
the IVC (the lesion that had decreased most in size from 
baseline) was contiguous with the bleed.
His anemia was treated with a transfusion of 2 units of 
packed red blood cells, following which the hemoglobin 
rose to 11.5 gm/dL. The daily dosage of imatinib was 
decreased to 400 mg, as per the study protocol. The pa-
tient was not hospitalized. Over the next three weeks, the 
patient progressively improved, with significant decrease 
in his right upper quadrant pain and flank tenderness. The 
patient’s blood count was monitored on a weekly basis for 
several weeks. The patient became asymptomatic six weeks 
after the transfusion. A follow-up CT scan 3 months later 
(7 months after initiation of therapy) showed that the 
hematoma had nearly completely resolved (Fig. 1D). The 
size of the liver metastases continued to show significant 
improvement; the lesion lateral to the IVC had become 
imperceptible. 
Case Report 2
A 57-year-old woman presented four years prior to the 
bleeding incident with vomiting and abdominal pain. At 
that time she had been diagnosed with a 20 cm mass in 
the pelvis, adherent to the small intestine. The tumor was 
resected, and pathology confirmed the diagnosis of c-kit 
positive GIST. Two years later, a CT scan revealed three 
abdominal masses in the right upper quadrant; a second 
surgical procedure was performed to remove these lesions. 
The patient was started on ET-743 and then CT-2584 ex-
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Figure 1C. Contrast enhanced axial CT scan through the liver 
4months after initiation of imatinib therapy, demonstrates 
a large variable density subcapsular liver collection, likely 
hematoma.
Figure 1D. Follow up contrast enhanced axial CT scan 
through the liver 7 months following initiation of imatinib 
therapy demonstrates near complete resolution of subcap-
sular liver hematoma.
perimental chemotherapy protocols; these failed to control 
disease progression. A third operation was performed six 
months later as a palliative measure, during which several 
large intra-abdominal masses were resected. Numerous 
liver lesions were noted intraoperatively. Intraoperative 
biopsy proved these to be metastases as well.
Approximately 3 years after the initial diagnosis, the 
patient began treatment with imatinib. A baseline CT scan 
showed multiple metastatic lesions in the liver (Fig. 2A). 
The patient presented to the emergency department with 
nausea, vomiting, and abdominal pain five days after ini-
tiating treatment. She was found to have a fever of 101.1 
and a hematocrit of 24.4%, compared to 38% five days 
earlier. A CT scan at this time revealed new high attenua-
tion fluid in the abdomen and pelvis, and around the liver. 
The patient was admitted urgently and a blood transfusion 
(4 units of packed cells) was given to correct her anemia. 
The patient was taken off imatinib for 3 days, but restarted 
after 2 weeks after she had stabilized.
A CT scan two months later continued to show high at-
tenuation density in the abdomen and pelvis. A repeat scan 
five months later revealed a subcapsular hepatic hematoma 
(Fig. 2B) that was not as well-appreciated in the earlier 
scans, possibly owing to generalized intraperitoneal fluid; 
the hematoma was likely present the whole time. The liver 
lesions were decreased in size, as in the first case.
Discussion
These patients illustrate that hepatic subcapsular hema-
toma is a potential complication when imatinib is used to 
treat metastatic GIST. Both of our patients developed the 
subcapsular hematomas in the liver within four months of 
initiation of treatment with imatinib. They both lost sub-
stantial amounts of blood for which transfusions clinically 
were necessary to stabilize the patients.
Although its long term efficacy, susceptibility to recur-
rence, and safety are still being evaluated, imatinib has 
shown significant promise in treating GIST [2]. In past 
studies, the most commonly reported side effects included 
nausea, vomiting, diarrhea, and headache [2, 5]. In these 
studies, some patients showed internal bleeding, elevated 
liver function tests, and severe abdominal pain. These 
studies have shown a low number of such occurrences 
(less than 20%), and the potential risk in using the drug 
was outweighed by the invariably lethal consequences of 
metastatic GIST when left untreated, or when treated with 
other currently available chemotherapeutic regimens.
The subcapsular liver hematomas in our two patients 
were likely caused by some element of the tumor’s response 
to imatinib versus other more common causes. One com-
mon cause of subcapsular hematoma is iatrogenic injury. 
The most common etiology for iatrogenic hepatic subcap-
sular hematoma is percutaneous liver biopsy [6]. These 
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Figure 2A. 59-year-old woman with metastatic GIST. Baseline 
contrast-enhanced CT scan demonstrates multiple liver 
masses.
Figure 2B. Follow up contrast enhanced CT scan through the 
liver several months following the acute episode within a 
week of therapy clearly shows the subcapsular liver hema-
toma. The previously present masses are smaller.
bleeds have always been found to occur within two weeks 
of the procedure [7]. The patient in the first case report 
did have a liver biopsy; however, a CT scan performed 
two months later showed no signs of hemorrhage, and the 
lesion biopsied was likely not the tumor that bled. In addi-
tion, the patient had no symptoms immediately after this 
biopsy. The absence of CT or physical findings following 
the biopsy make it unlikely to have been the cause for this 
patient’s hemorrhage.
Another possible cause of subcapsular hematoma is that 
it was secondary to a spontaneously hemorrhaging lesion. 
This cannot be fully excluded in our patients, but it is 
unlikely due to the close association between the treat-
ment and the hemorrhagic episode. Bleeding into a liver 
tumor is not, in and of itself, uncommon. The commonest 
underlying tumors are hepatocellular carcinoma or hepatic 
adenoma [8].
It is likely that the subcapsular liver hematoma in our 
patient was caused by the tumor’s response to imatinib. 
The mechanism of the bleeding could be from rupturing 
of vessels secondary to a rapidly retracting and shrinking 
tumor. In the first case, the lesion that responded the most 
to imatinib was shown radiographically to be contiguous 
communicate with the hemorrhagic collection. The second 
case also supports the association between response of liver 
metastatic GIST to imatinib and the resulting subcapsular 
liver hematoma although it is not possible to be certain 
regarding the lesion that caused the hemorrhage.
As the indications for imatinib increase and its efficacy 
in treating GIST is further established, it is important for 
radiologists not to misread the occurrence of subcapsular 
hematoma as being a sign of progression of disease. Al-
though the development of a liver subcapsular hematoma 
is apparently a sign of improvement, these findings, i.e., 
the hematoma itself , and possibly intraperitoneal hemor-
rhage (secondary to bleeding from intraperitoneal metasta-
ses) should be considered potentially life threatening. This 
fact should be kept in mind when evaluating images of 
patients with GIST being treated with imatinib. Awareness 
of this potential complication should result in earlier diag-
nosis and treatment of blood loss and anemia, and could 
thus decrease overall morbidity and mortality. 
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